Exelixis, Inc.
EXELExelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Drugs in Pipeline
7
Phase 3 Programs
6
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How EXEL's past catalysts played out
Regorafenib
Colorectal Cancer
XL184
Glioblastoma Multiforme
Cabozantinib
Solid Tumors
XL092
Non-Clear Cell Renal Cell Carcinoma
Zanzalintinib
Head and Neck Squamous Cell Carcinoma
Cabozantinib tablets
Renal Cell Carcinoma
XL820
Gastrointestinal Stromal Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Regorafenib | Phase 3 | Colorectal Cancer | - | - |
XL184 | Phase 3 | Glioblastoma Multiforme | - | - |
Cabozantinib | Phase 3 | Solid Tumors | - | - |
XL092 | Phase 3 | Non-Clear Cell Renal Cell Carcinoma | - | - |
Zanzalintinib | Phase 3 | Head and Neck Squamous Cell Carcinoma | - | - |
Cabozantinib tablets | Phase 3 | Renal Cell Carcinoma | - | - |
XL820 | Phase 2 | Gastrointestinal Stromal Tumors | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Exelixis, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Exelixis, Inc.'s (EXEL) pipeline across Phase 3, Phase 2. Its lead program is Regorafenib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Exelixis, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Exelixis, Inc. (EXEL) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track EXEL biotech catalysts?→
Add EXEL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Exelixis, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.